Option Care Health, Inc. (OPCH)

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.

Ticker
OPCH
Exchange
Nasdaq
Sector
Healthcare
Industry
Medical Care Facilities
Market cap
$4.74B
52-week range
$18.01 - $36.80

Valuation

Share price
$31.65 (close of Nov 6, 2026)
P/E (TTM)
22.77x
Price to book
3.58x
Price to free cash flow
16.83x
Enterprise value
$5.70B
Book value per share
$8.84

Price performance

PeriodChange
1 day+0.48%
5 days-0.57%
1 month+2.10%
3 months+33.94%
6 months+54.77%
Year to date-0.66%
1 year+17.05%
3 years+10.28%
5 years+13.36%
10 years+203.16%
All time-36.70%

Short interest

As of
Oct 15, 2026
Short % of float
6.62%
Shares short
7.12M
Days to cover
0.64
Change since prior report
-16.86%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
15.65%
Return on invested capital
10.10%
Return on assets
6.01%
Return on capital employed
12.87%
Gross margin
19.26%
Net margin
3.67%
EBITDA margin
7.23%
Revenue growth
13.03%
Net income growth
-2.00%
Free cash flow growth
-24.55%

Cash flow and balance sheet

Free cash flow yield (TTM)
5.94%
Current ratio
1.54x
Net debt to EBITDA
2.29x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$5.65B
Cost of revenue
$4.56B
Gross profit
$1.09B
EBITDA
$408.60M
Net income
$207.59M
Earnings per share
$1.28
Interest expense
$54.56M
Shares outstanding
162.10M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$5.65B$1.09B$207.59M$1.28
2024-12-31$5.00B$1.01B$211.82M$1.23
2023-12-31$4.30B$981.22M$267.09M$1.49
2022-12-31$3.87B$866.92M$150.56M$0.83
2021-12-31$3.44B$779.61M$139.90M$0.78
2020-12-31$3.03B$682.26M-$8.08M-$0.04
2019-12-31$2.31B$513.00M-$75.92M-$0.49
2018-12-31$1.94B$422.21M-$6.12M-$0.04
2017-12-31$1.83B$446.00M$3.88M$0.03
2016-12-31$935.59M$262.08M-$42.77M-$2.20

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3119.26%3.67%15.65%10.10%
2024-12-3120.27%4.24%15.08%9.54%
2023-12-3122.81%6.21%18.79%8.61%
2022-12-3122.41%3.89%10.86%7.28%
2021-12-3122.67%4.07%11.90%8.17%
2020-12-3122.50%-0.27%-0.80%4.84%
2019-12-3122.20%-3.29%-8.37%-0.01%
2018-12-3121.77%-0.32%-1.01%3.35%
2017-12-3124.40%0.21%0.64%2.46%
2016-12-3128.01%-4.57%-7.12%-1.01%

Cash and debt by year

Period endCashDebt
2025-12-31$232.62M$1.15B
2024-12-31$412.56M$1.10B
2023-12-31$343.85M$1.06B
2022-12-31$294.19M$1.06B
2021-12-31$119.42M$1.06B
2020-12-31$99.27M$1.12B
2019-12-31$67.06M$1.28B
2018-12-31$36.39M$535.23M
2017-12-31$39.46M$502.86M
2016-12-31$9.57M$467.72M

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$217.14M$39.96M
2024-12-31$287.79M$36.14M
2023-12-31$329.43M$30.48M
2022-12-31$232.19M$16.78M
2021-12-31$182.94M$9.57M
2020-12-31$100.52M$2.92M
2019-12-31$11.18M$4.17M
2018-12-31-$1.85M$2.14M
2017-12-31$12.91M$1.46M
2016-12-31-$42.54M$1.80M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-04Sep 2026$0.44
2026-07-29Jun 2026$0.37
2026-04-30Mar 2026$0.34
2026-02-24Dec 2025$0.41
2025-10-30Sep 2025$0.38
2025-07-30Jun 2025$0.36
2025-04-29Mar 2025$0.32
2025-02-26Dec 2024$0.33

Filings and sources

Company website
optioncarehealth.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

HCA Healthcare, Inc. (HCA) · DaVita Inc. (DVA) · Universal Health Services Inc (UHS) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · Natera, Inc. (NTRA) · Agilent Technologies, Inc. (A) · IQVIA Holdings Inc. (IQV)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades